CardioDx, Inc. Uses Revolution Analytics to Develop First Non-Intrusive Test for Predicting Coronary Artery Disease

1/18/2011 10:09:49 AM

PALO ALTO, Calif.--(BUSINESS WIRE)--Revolution Analytics, the leading provider of commercial software and support for the popular open source R statistics language, today announced the successful implementation of its signature product, Revolution R Enterprise, by biostatisticians at CardioDX, a genomic research firm. Revolution R was used to design the Corus CAD® test, the first test of its kind to analyze genomic data and identify at-risk patients for coronary artery disease (CAD) without requiring an invasive procedure. The Corus CAD® test was recently honored as one of TIME Magazine’s “Top Ten Medical Breakthroughs of 2010”.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• CardioDx, Inc.

• Diagnostics

• Medical Dev. & Diag. - Software